본문 바로가기
KERD
논문KCI 등재

Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons

Liu Xin|Chen Yu|Gao Yuan|Gao Yunyi|Duan Meili|Hou Bing
거트앤리버 소화기연관학회협의회|2024.11|Gut and Liver|제18권 제6호|pp. 934-948|DOI 10.5009/gnl240038

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

AscitesRenin-angiotensin systemSodium-glucose transporter 2 inhibitorsLiver cirrhosisFinerenone

초록

Ascites is the most common complication in patients with decompensated cirrhosis. This condition results in a severely impaired quality of life, excessive healthcare use, recurrent hospitalizations and significant morbidity and mortality. While loop diuretics and mineralocorticoid receptor antagonists are commonly employed for symptom relief, our understanding of their impact on survival remains limited. A comprehensive understanding of the underlying pathophysiological mechanism of ascites is crucial for its optimal management. The renin-angiotensin-aldosterone system (RAAS) is increasingly believed to play a pivotal role in the formation of cirrhotic ascites, as RAAS overactivation leads to a reduction in urine sodium excretion then a decrease in the ability of the kidneys to excrete water. In this review, the authors provide an overview of the pathogenesis of cirrhotic ascites, the challenges associated with current pharmacologic treatments, and the previous attempts to modulate the RAAS, followed by a description of some emerging targeted RAAS agents with the potential to be used to treat ascites.

Abstract

Ascites is the most common complication in patients with decompensated cirrhosis. This condition results in a severely impaired quality of life, excessive healthcare use, recurrent hospitalizations and significant morbidity and mortality. While loop diuretics and mineralocorticoid receptor antagonists are commonly employed for symptom relief, our understanding of their impact on survival remains limited. A comprehensive understanding of the underlying pathophysiological mechanism of ascites is crucial for its optimal management. The renin-angiotensin-aldosterone system (RAAS) is increasingly believed to play a pivotal role in the formation of cirrhotic ascites, as RAAS overactivation leads to a reduction in urine sodium excretion then a decrease in the ability of the kidneys to excrete water. In this review, the authors provide an overview of the pathogenesis of cirrhotic ascites, the challenges associated with current pharmacologic treatments, and the previous attempts to modulate the RAAS, followed by a description of some emerging targeted RAAS agents with the potential to be used to treat ascites.

참고문헌 (140)

  1. European Association for the Study of the Liver, "EASL clinical practice guidelines for the management of patients with decompensated cirrhosis", J Hepatol, 69, pp.406~460 (2018)
  2. European Association for the Study of the Liver, "EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis", J Hepatol, 53, pp.397~417 (2010)
  3. Hudson B, "Cirrhosis with ascites in the last year of life : a nationwide analysis of factors shaping costs, health-care use, and place of death in England", Lancet Gastroenterol Hepatol, 3, pp.95~103 (2018)
  4. Volk ML, "Hospital readmissions among patients with decompensated cirrhosis", Am J Gastroenterol, 107, pp.247~252 (2012)
  5. Arroyo V, "Pathophysiological basis of albumin use in cirrhosis", Ann Hepatol, 10(Suppl 1), pp.S6~S14 (2011)
  6. Giannelli V, "Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation", J Hepatol, 72, pp.463~471 (2020)
  7. Iwakiri Y, "Pathophysiology of portal hypertension", Clin Liver Dis, 18, pp.281~291 (2014)
  8. Iwakiri Y, "The molecules : mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension", J Clin Gastroenterol, 41(Suppl 3), pp.S288~S294 (2007)
  9. Iwakiri Y, "Vascular endothelial dysfunction in cirrhosis", J Hepatol, 46, pp.927~934 (2007)
  10. Chodorowski Z, "Carbon monoxide : a regulator of vascular tone in hypoxia?", Przegl Lek, 62, pp.438~440 (2005)
  11. Stitham J, "Versatility and differential roles of cysteine residues in human prostacyclin receptor structure and function", J Biol Chem, 281, pp.37227~37236 (2006)
  12. Pesce M, "Endocannabinoids in the treatment of gasytrointestinal inflammation and symptoms", Curr Opin Pharmacol, 43, pp.81~86 (2018)
  13. Alukal JJ, "Hyponatremia in cirrhosis : an update", Am J Gastroenterol, 115, pp.1775~1785 (2020)
  14. Barrera-Chimal J, "Mineralocorticoid receptor antagonists and kidney diseases : pathophysiological basis", Kidney Int, 96, pp.302~319 (2019)
  15. John S, "Hyponatremia in cirrhosis : pathophysiology and management", World J Gastroenterol, 21, pp.3197~3205 (2015)
  16. Chinese Society of Hepatology, "Chinese guidelines on the management of ascites and its related complications in cirrhosis", Hepatol Int, 13, pp.1~21 (2019)
  17. Felker GM, "Diuretic therapy for patients with heart failure : JACC state-ofthe-art review", J Am Coll Cardiol, 75, pp.1178~1195 (2020)
  18. Gardiner P, "Spironolactone metabolism : steady-state serum levels of the sulfur-containing metabolites", J Clin Pharmacol, 29, pp.342~347 (1989)
  19. Sungaila I, "Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites", Gastroenterology, 102, pp.1680~1685 (1992)
  20. de Denus S, "Spironolactone metabolite concentrations in decompensated heart failure : insights from the ATHENA-HF trial", Eur J Heart Fail, 22, pp.1451~1461 (2020)
  21. Barrera-Chimal J, "Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists : head-to-head comparisons of pharmacological and clinical characteristics", Expert Opin Investig Drugs, 30, pp.1141~1157 (2021)
  22. Bakris GL, "Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial", Am J Nephrol, 50, pp.333~344 (2019)
  23. Yang P, "The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease : progress and challenges", Metabolism, 65, pp.1342~1349 (2016)
  24. Pitt B, "Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease : a randomized, double-blind trial", Eur Heart J, 34, pp.2453~2463 (2013)
  25. Bakris GL, "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes", N Engl J Med, 383, pp.2219~2229 (2020)
  26. Pitt B, "Cardiovascular events with finerenone in kidney disease and type 2 diabetes", N Engl J Med, 385, pp.2252~2263 (2021)
  27. Zeidel ML, "Salt and water : not so simple", J Clin Invest, 127, pp.1625~1626 (2017)
  28. Bankir L, "Vaptans or voluntary increased hydration to protect the kidney : how do they compare?", Nephrol Dial Transplant, 38, pp.562~574 (2023)
  29. Yan L, "The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites : a metaanalysis of randomized controlled trials", BMC Gastroenterol, 15, pp.65~ (2015)
  30. Wong F, "Satavaptan for the management of ascites in cirrhosis : efficacy and safety across the spectrum of ascites severity", Gut, 61, pp.108~116 (2012)
  31. Gheorghiade M, "Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure : a randomized controlled trial", JAMA, 291, pp.1963~1971 (2004)
  32. Gheorghiade M, "Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : the EVEREST Clinical Status Trials", JAMA, 297, pp.1332~1343 (2007)
  33. Konstam MA, "Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial", JAMA, 297, pp.1319~1331 (2007)
  34. Torres VE, "Tolvaptan in patients with autosomal dominant polycystic kidney disease", N Engl J Med, 367, pp.2407~2418 (2012)
  35. Aithal GP, "Guidelines on the management of ascites in cirrhosis", Gut, 70, pp.9~29 (2021)
  36. Bansal S, "Sodium retention in heart failure and cirrhosis : potential role of natriuretic doses of mineralocorticoid antagonist?", Circ Heart Fail, 2, pp.370~376 (2009)
  37. Bichet DG, "Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis", N Engl J Med, 307, pp.1552~1557 (1982)
  38. Berl T, "Prostaglandins in the beta-adrenergic and baroreceptor-mediated secretion of renin", Am J Physiol, 236, pp.F472~F477 (1979)
  39. Wong RJ, "Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites : a meta-analysis", Liver Int, 39, pp.1080~1088 (2019)
  40. Ohnishi A, "Renal and hormonal responses to repeated treatment with enalapril in non-azotemic cirrhosis with ascites", J Hepatol, 20, pp.223~230 (1994)
  41. Gentilini P, "Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver", Gastroenterology, 104, pp.588~594 (1993)
  42. Daskalopoulos G, "Effects of captopril on renal function in patients with cirrhosis and ascites", J Hepatol, 4, pp.330~336 (1987)
  43. Tsai YT, "Effects of captopril on renal functions, renal and portal hemodynamics in patients with cirrhosis", Proc Natl Sci Counc Repub China B, 20, pp.44~50 (1996)
  44. Saffo S, "SGLT2 inhibitors and cirrhosis : a unique perspective on the comanagement of diabetes mellitus and ascites", Clin Liver Dis(Hoboken), 11, pp.141~144 (2018)
  45. Fung JW, "Effect of beta blockade(carvedilol or metoprolol)on activation of the reninangiotensin-aldosterone system and natriuretic peptides in chronic heart failure", Am J Cardiol, 92, pp.406~410 (2003)
  46. Tsuyuki RT, "Beta-blockers for congestive heart failure : what is the current consensus?", Drugs Aging, 16, pp.1~7 (2000)
  47. Villanueva C, "β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI) : a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 393, pp.1597~1608 (2019)
  48. Villanueva C, "Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis", J Hepatol, 77, pp.1014~1025 (2022)
  49. Tergast TL, "Effects of renin-angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis", Sci Rep, 13, pp.17486~ (2023)
  50. Danielsen KV, "Effect of beta-blockers on multiple haemodynamics in cirrhosis : a cross-over study by MR-imaging and hepatic vein catheterization", Liver Int, 43, pp.2245~2255 (2023)
  51. Nabilou P, "Blunted cardiovascular effects of beta-blockers in patients with cirrhosis : relation to severity?", PLoS One, 17, pp.e0270603~ (2022)
  52. Singh V, "Propranolol vs. band ligation for primary prophylaxis of variceal hemorrhage in cirrhotic patients with ascites : a randomized controlled trial", Hepatol Int, 16, pp.944~953 (2022)
  53. Chen YC, "Propranolol use in patients with cirrhosis and refractory ascites : a nationwide study", Saudi J Gastroenterol, 28, pp.108~114 (2022)
  54. Tapper EB, "Incidence of, risk factors for, and outcomes after ascites in a populationbased cohort of older Americans", Dig Dis Sci, 67, pp.5327~5335 (2022)
  55. Kang SH, "The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension : real-world multicenter study", Hepatol Int, 15, pp.424~436 (2021)
  56. Sasso R, "Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection", Aliment Pharmacol Ther, 53, pp.418~425 (2021)
  57. McDowell HR, "Carvedilol is associated with improved survival in patients with cirrhosis : a long-term follow-up study", Aliment Pharmacol Ther, 53, pp.531~539 (2021)
  58. Kalambokis GN, "Conversion of propranolol to carvedilol improves renal perfusion and outcome in patients with cirrhosis and ascites", J Clin Gastroenterol, 55, pp.721~729 (2021)
  59. Téllez L, "Nonselective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites", J Hepatol, 73, pp.1404~1414 (2020)
  60. Alvarado-Tapias E, "Shortterm hemodynamic effects of beta-blockers influence survival of patients with decompensated cirrhosis", J Hepatol, 73, pp.829~841 (2020)
  61. Yoo JJ, "Propranolol plus endoscopic ligation for variceal bleeding in patients with significant ascites : Propensity score matching analysis", Medicine(Baltimore), 99, pp.e18913~ (2020)
  62. Ngwa T, "Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation", BMC Gastroenterol, 20, pp.4~ (2020)
  63. Tergast TL, "Systemic arterial blood pressure determines the therapeutic window of nonselective beta blockers in decompensated cirrhosis", Aliment Pharmacol Ther, 50, pp.696~706 (2019)
  64. Chen WC, "Addition of carvedilol to gastric variceal obturation does not decrease recurrence of gastric variceal bleeding in patients with cirrhosis", Clin Gastroenterol Hepatol, 17, pp.2356~2363 (2019)
  65. Giannitrapani L, "Nontumorous portal vein thrombosis in liver cirrhosis : possible role of beta-blockers", Med Princ Pract, 27, pp.466~471 (2018)
  66. Zampino R, "The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients", Saudi J Gastroenterol, 24, pp.25~29 (2018)
  67. Pfisterer N, "Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding", Aliment Pharmacol Ther, 47, pp.966~979 (2018)
  68. Onali S, "Non-selective betablockers are not associated with increased mortality in cirrhotic patients with ascites", Liver Int, 37, pp.1334~1344 (2017)
  69. Sinha R, "Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites", J Hepatol, 67, pp.40~46 (2017)
  70. Kim SG, "Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates", Liver Transpl, 23, pp.733~740 (2017)
  71. Bossen L, "Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites : post hoc analysis of three randomized controlled trials with 1198 patients", Hepatology, 63, pp.1968~1976 (2016)
  72. Mookerjee RP, "Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure", J Hepatol, 64, pp.574~582 (2016)
  73. Mandorfer M, "Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis", Gastroenterology, 146, pp.1680~1690 (2014)
  74. Sersté T, "Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites : a cross-over study", J Hepatol, 55, pp.794~799 (2011)
  75. Sersté T, "Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites", Hepatology, 52, pp.1017~1022 (2010)
  76. Therapondos G, "The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis", Hepatology, 44, pp.640~649 (2006)
  77. Cholongitas E, "Spontaneous bacterial peritonitis in cirrhotic patients : is prophylactic propranolol therapy beneficial?", J Gastroenterol Hepatol, 21, pp.581~587 (2006)
  78. Groszmann RJ, "Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis", N Engl J Med, 353, pp.2254~2261 (2005)
  79. Abecasis R, "Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients : a preliminary study", Hepatology, 37, pp.359~365 (2003)
  80. Sen S, "Hemodynamic effect of spironolactone in liver cirrhosis and propranolol-resistant portal hypertension", Indian J Gastroenterol, 21, pp.145~148 (2002)
  81. Wong F, "The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis", Hepatology, 35, pp.1449~1458 (2002)
  82. De BK, "Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics", J Gastroenterol Hepatol, 17, pp.183~189 (2002)
  83. Lee JK, "Effects of single dose of 50mg captopril in patients with liver cirrhosis and ascites", Hepatogastroenterology, 47, pp.767~770 (2000)
  84. Forrest EH, "Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis", J Hepatol, 25, pp.909~915 (1996)
  85. Amarapurkar DN, "Role of routine estimation of creatinine clearance in patients with liver cirrhosis", Indian J Gastroenterol, 13, pp.79~82 (1994)
  86. van Vliet AA, "Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis", J Hepatol, 15, pp.40~47 (1992)
  87. Ibarra FR, "Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis", Eur J Clin Pharmacol, 43, pp.477~482 (1992)
  88. Poynard T, "Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group", N Engl J Med, 324, pp.1532~1538 (1991)
  89. The Italian Multicenter Project for Propranolol in Prevention of Bleeding, "Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial", J Hepatol, 9, pp.75~83 (1989)
  90. Pariente EA, "Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites", Gastroenterology, 88(5 Pt 1), pp.1255~1259 (1985)
  91. Rector WG Jr, "Propranolol in the treatment of cirrhotic ascites", Arch Intern Med, 144, pp.1761~1763 (1984)
  92. Lebrec D, "A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis : a final report", Hepatology, 4, pp.355~358 (1984)
  93. Bernardi M, "Albumin in decompensated cirrhosis : new concepts and perspectives", Gut, 69, pp.1127~1138 (2020)
  94. McCormick PA, "Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites", Gut, 31, pp.204~207 (1990)
  95. Gentilini P, "Albumin improves the response to diuretics in patients with cirrhosis and ascites : results of a randomized, controlled trial", J Hepatol, 30, pp.639~645 (1999)
  96. Laffi G, "Is the use of albumin of value in the treatment of ascites in cirrhosis?", The case in favour. Dig Liver Dis, 35, pp.660~663 (2003)
  97. Romanelli RG, "Long-term albumin infusion improves survival in patients with cirrhosis and ascites : an unblinded randomized trial", World J Gastroenterol, 12, pp.1403~1407 (2006)
  98. Caraceni P, "Long-term albumin administration in decompensated cirrhosis(ANSWER) : an open-label randomised trial", Lancet, 391, pp.2417~2429 (2018)
  99. Bernardi M, "Albumin infusion in patients undergoing large-volume paracentesis : a meta-analysis of randomized trials", Hepatology, 55, pp.1172~1181 (2012)
  100. Shasthry SM, "Changes in cardiac output and incidence of volume overload in cirrhotics receiving 20% albumin infusion", Liver Int, 37, pp.1167~1176 (2017)
  101. Luca A, "Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis", Hepatology, 22, pp.753~758 (1995)
  102. China L, "A randomized trial of albumin infusions in hospitalized patients with cirrhosis", N Engl J Med, 384, pp.808~817 (2021)
  103. Elizalde JI, "Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients", J Hepatol, 29, pp.789~795 (1998)
  104. Fernández J, "Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis", Gastroenterology, 157, pp.149~162 (2019)
  105. Quon CY, "Clinical pharmacokinetics and pharmacodynamics of colloidal plasma volume expanders", Journal of Cardiothoracic Anesthesia, 2, pp.13~23 (1988)
  106. Schieffer B, "Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques : potential implications for inflammation and plaque instability", Circulation, 101, pp.1372~1378 (2000)
  107. Catar R, "IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane", J Am Soc Nephrol, 28, pp.1188~1199 (2017)
  108. Uriz J, "Terlipressin plus albumin infusion : an effective and safe therapy of hepatorenal syndrome", J Hepatol, 33, pp.43~48 (2000)
  109. Fernández J, "Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis", J Hepatol, 41, pp.384~390 (2004)
  110. Bortoluzzi A, "Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites : molecular mechanisms", Hepatology, 57, pp.266~276 (2013)
  111. Fernández J, "A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis", Hepatology, 42, pp.627~634 (2005)
  112. Walley KR, "Albumin resuscitation increases cardiomyocyte contractility and decreases nitric oxide synthase II expression in rat endotoxemia", Crit Care Med, 31, pp.187~194 (2003)
  113. Arroyo V, "Human serum albumin, systemic inflammation, and cirrhosis", J Hepatol, 61, pp.396~407 (2014)
  114. Kremer H, "Human serum albumin improves endothelial dysfunction and survival during experimental endotoxemia : concentration-dependent properties", Crit Care Med, 39, pp.1414~1422 (2011)
  115. Salerno F, "Refractory ascites : pathogenesis, definition and therapy of a severe complication in patients with cirrhosis", Liver Int, 30, pp.937~947 (2010)
  116. Gatta A, "A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients", Hepatology, 14, pp.231~236 (1991)
  117. Washburn WN, "Differentiating sodiumglucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus", Expert Opin Investig Drugs, 22, pp.463~486 (2013)
  118. Braunwald E, "Gliflozins in the management of cardiovascular disease", N Engl J Med, 386, pp.2024~2034 (2022)
  119. Tanaka H, "Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus", Adv Ther, 34, pp.436~451 (2017)
  120. Verma A, "SGLT2 inhibitor : not a traditional diuretic for heart failure", Cell Metab, 32, pp.13~14 (2020)
  121. Packer M, "Cardiovascular and renal outcomes with empagliflozin in heart failure", N Engl J Med, 383, pp.1413~1424 (2020)
  122. McMurray JJ, "Dapagliflozin in patients with heart failure and reduced ejection fraction", N Engl J Med, 381, pp.1995~2008 (2019)
  123. Gao Y, "SGLT2 inhibitors : a new dawn for recurrent", refractory cirrhotic ascites, 2021, pp.9, 795~797
  124. Mordi NA, "Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure : the RECEDE-CHF trial", Circulation, 142, pp.1713~1724 (2020)
  125. Kalambokis GN, "Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis", Am J Gastroenterol, 116, pp.618~619 (2021)
  126. Miyamoto Y, "Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor", Clin Kidney J, 15, pp.831~833 (2022)
  127. Montalvo-Gordon I, "Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes", Hepatology, 72, pp.1880~1882 (2020)
  128. Yeoh SE, "Relationship of dapagliflozin with serum sodium : findings from the DAPA-HF trial", JACC Heart Fail, 10, pp.306~318 (2022)
  129. Li S, "Impact of SGLT2 inhibitors on serum sodium in heart failure with reduced ejection fraction", JACC Heart Fail, 10, pp.319~320 (2022)
  130. Katsurada K, "Enhanced expression and function of renal SGLT2(sodium-glucose cotransporter 2)in heart failure : role of renal nerves", Circ Heart Fail, 14, pp.e008365~ (2021)
  131. Pfortmueller CA, "Hypoglycemia is associated with increased mortality in patients with acute decompensated liver cirrhosis", J Crit Care, 29, pp.316~ (2014)
  132. Polidori D, "Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus", J Clin Endocrinol Metab, 98, pp.E867~E871 (2013)
  133. Zannad F, "SGLT2 inhibitors in patients with heart failure with reduced ejection fraction : a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials", Lancet, 396, pp.819~829 (2020)
  134. Kasichayanula S, "Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin : an open-label, parallel-group, single-dose study", Clin Ther, 33, pp.1798~1808 (2011)
  135. Macha S, "Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment", Diabetes Obes Metab, 16, pp.118~123 (2014)
  136. Devineni D, "Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor", Clin Ther, 37, pp.610~628 (2015)
  137. Zelniker TA, "Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors : JACC state-of-the-art review", J Am Coll Cardiol, 75, pp.422~434 (2020)
  138. Ansary TM, "Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system", Int J Mol Sci, 20, pp.629~ (2019)
  139. Griffin M, "Empagliflozin in heart failure : diuretic and cardiorenal effects", Circulation, 142, pp.1028~1039 (2020)
  140. Miyamoto Y, "The effects of SGLT2 inhibitors on liver cirrhosis patients with refractory ascites : a literature review", J Clin Med, 12, pp.2253~ (2023)

관련 논문AI추천

Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension엄영우, Kwang Yong Shim, Moon Young Kim, Seong Hee Kang, Soon Koo Baik대한내과학회 · The Korean Journal of Internal Medicine2018 · 제33권 제3호Effect of a Diet with Unrestricted Sodium on Ascites in Patients with Hepatic CirrhosisBo-yu Xu, Hong-ying Zhu, Xiao-juan Yang, Xi-bing Gu거트앤리버 소화기연관학회협의회 · Gut and Liver2012 · 제6권 제3호Management of refractory ascitesFlorence Wong대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호간경변성 복수 환자에서 Vaptan계열 약제의 유용성이준성, 최원혁대한내과학회 · 대한내과학회지2012 · 제82권 제1호The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunctionAyman Alsebaey, Eman Abdelsamee, Eman Rewisha, Maha Mohammad Elsabaawy, Manar Abdelaal Obada, Shimaa Rashad Abdelhamid, Tary Abdelhamid Salman대한간학회 · Clinical and Molecular Hepatology2015 · 제21권 제4호Hepatorenal syndrome: Current concepts and future perspectivesChan-Young Jung, Jai Won Chang대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제4호

이 간행물의 다른 논문 (16건)

Thickened Gastric Wall: Simplifying the DiagnosisLee Jong Yeul, 김준성pp. 929-930Can Patients with Clarithromycin-Resistant Helicobacter pylori Infection Be Treated with a 7-Day Bismuth-Based Quadruple Therapy?Kim Jung-Wook, Kim Albert C.pp. 931-933Cellular Plasticity in Gut and Liver RegenerationKim Minwook, Kim You Sun, Park Yoojeong, Ko Sungjinpp. 949-960Differential Diagnosis of Thickened Gastric Wall between Hypertrophic Gastritis and Borrmann Type 4 Advanced Gastric CancerLee Gin Hyug, Seo Jun-young, Kim Hwa Jung, Jung Hwoon-Yong, Ahn Ji Yong, Choi Kee Don, Na Hee Kyong, Jung Kee Wook, Lee Jeong Hoon, Kim Do Hoon, Song Ho Junepp. 961-969Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens오정환, 임철현pp. 970-976
원문 보기